

<120> ANTIBODY HAVING A T-CELL RECEPTOR-LIKE SPECIFICITY, YET HIGHER AFFINITY, AND THE USE OF SAME IN THE DETECTION AND TREATMENT OF CANCER, VIRAL INFECTION AND AUTOIMMUNE DISEASE

<130> 01/23094

<160> 11

<170> PatentIn version 3.1

<210> 1

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, gp100 (154)

<400> 1

Lys Thr Trp Gly Gln Tyr Trp Gln Val
1 5

<210> 2

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, gp100 (209)

<400> 2

Ile Met Asp Gln Val Pro Phe Ser Val
1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, gp100 (280)

<400> 3

Tyr Leu Glu Pro Gly Pro Val Thr Val
1 5

<210> 4

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, MUC1

2025-10-20 10:00:00

<400> 4

Leu Leu Leu Thr Val Leu Thr Val Leu

1 5

<210> 5

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, HTLV-1 (TAX)

<400> 5

Leu Leu Phe Gly Tyr Pro Val Tyr Val

1 5

<210> 6

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, hTERT room temperature (540)

<400> 6

Ile Leu Ala Lys Phe Leu His Trp Leu

1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2-restricted peptide, hTeroom temperature (865)

<400> 7

Arg Leu Val Asp Asp Phe Leu Leu Val

1

5

<210> 8

<211> 711

<212> DNA

<213> Artificial sequence

<220>

<223> G1 Single chain Fv-recombinant antibody DNA sequence

<400> 8

cagggtgaaac tgcaggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cactttcagt agctatggca tgtottgggt tcgccagact 120

ccagacaaga ggctggagtg ggtcgcaacc attagtagtg gtggtagtta cacctactat 180

ccagacagtg tgaaggggag attcaccatc tcagagaca atgccaagaa caccctgtac 240

ctgcaaata gacagtctgaa gtctgaggac acagccatgt attactgtgc aagaggtaac 300
 tgggaaggat ggtacttcga tgtctggggc caagggacca cggtcacogt ctcctcaggt 360
 ggagcggtt caggcggagg tggtctggc ggtggcggat cgaacatcga gctcactcag 420
 tctccagcaa tcatgtctgc atctccagg gagaggggtca ccatgacctg cagtgccagc 480
 tcaagtatac gttacatata ttggtaccaa cagaagcctg gatcctcccc cagactcctg 540
 atttatgaca catccaacgt ggctcctgga gtcccttttc gcttcagtgg cagtgggtct 600
 gggacctctt attctctcac aatcaaccga atggaggctg aggatgctgc cacttattac 660
 tgccaggagt ggagtggta tccgtacacg ttcggagggg ggacaaagtt g 711

<210> 9

<211> 237

<212> PRT

<213> Artificial sequence

<220>

<223> G1 single chain Fv- recombinant antibody protein sequence

<400> 9

Gln Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val
 35 40 45

81

Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

Ala Arg Gly Asn Trp Glu Gly Trp Tyr Phe Asp Val Trp Gly Gln Gly
100 105 110

Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125

Ser Gly Gly Gly Gly Ser Asn Ile Glu Leu Thr Gln Ser Pro Ala Ile
130 135 140

Met Ser Ala Ser Pro Gly Glu Arg Val Thr Met Thr Cys Ser Ala Ser
145 150 155 160

Ser Ser Ile Arg Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser
165 170 175

Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Val Ala Pro Gly Val Pro
180 185 190

Phe Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
195 200 205

Asn Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Glu Trp
210 215 220

Ser Gly Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu

225

230

235

<210> 10

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Influenza derived HLA-restricted peptide

<400> 10

Gly Ile Leu Gly Phe Val Phe Thr Leu

1

5

<210> 11

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Hepatitis B derived HLA-restricted peptide

<400> 11